highrollerpoker| BAHEAL Pharmaceutical acquires 60% equity in BAHEAL Pharmaceutical for 880 million yuan

May 20highrollerpokerBaiyang Pharmaceutical (301015), the leader in the CXO industry, announced that the company plans to hold a total of 60% of Baiyang Pharmaceutical by acquiring equity in Baiyang Pharmaceutical, Baiyang Investment, Baiyang Yiren and Baiyang Kanghehighrollerpoker.199% equity, with a total transaction price of 880 million yuan.

After the transaction was completed, Baiyang Pharmaceutical controlled 61.794% equity of Baiyang Pharmaceutical and directly or indirectly held a total of 60.199% equity of Baiyang Pharmaceutical, becoming the controlling shareholder of Baiyang Pharmaceutical.

Baiyang Pharmaceutical is a pharmaceutical manufacturing enterprise focusing on the modernization of traditional Chinese medicine and the research and development and production of sustained and controlled release preparations. Its main products include the exclusive Chinese patent medicine variety Fuzheng Huayu in the field of liver disease, and metformin, nifedipine, celecoxib and other high-end preparations with sustained and controlled release preparation technology as the core.

From 2022 to 2023, Baiyang Pharmaceutical's operating income will be 635 million yuan and 760 million yuan respectively, and its net profit attributable to the parent company after deducting non-recurring gains and losses will be 8.8 million yuan respectively.highrollerpoker, 1.52 million yuan, 104 million yuan. Among them, the revenue from the Chinese patent medicine sector was 507 million yuan and 529 million yuan respectively.

As a company in the field of pharmaceutical circulation, Baiyang Pharmaceutical's main business at this stage covers three sectors: brand operation, wholesale and distribution, and retail. In 2023, Baiyang Pharmaceutical achieved revenue of 7.564 billion yuan, a year-on-year increase of 0.72%highrollerpoker; Net profit attributable to the parent company was 656 million yuan, a year-on-year increase of 29.55%.

Baiyang Pharmaceutical said that the purpose of this transaction is to extend the layout of listed companies in the pharmaceutical industry chain by creating business synergy with Baiyang Pharmaceutical, and upgrade from a health brand commercialization platform to a pharmaceutical industrialization platform that supports source innovation.

Tags:

Prev: largestlotteryjackpot| Haun Steam Power: Recently received a total of approximately 75 million yuan in project targets
Next: gameroomgames| A Singapore Airlines passenger plane made an emergency landing at Bangkok Airport, killing 1 person and injuring 30 others